Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB lineages have achieved dominance worldwide and keep on evolving. Convergent evolution of XBB lineages on the receptor-binding domain (RBD) L455F and F456L is observed, resulting in variants with substantial growth advantages, such as EG.5, FL.1.5.1, XBB.1.5.70, and HK.3. Here, we show that neutralizing antibody (NAb) evasion drives the convergent evolution of F456L, while the epistatic shift caused by F456L enables the subsequent convergence of L455F through ACE2 binding enhancement and further immune evasion. L455F and F456L evade RBD-targeting Class 1 public NAbs, reducing the neutralization efficacy of XBB breakthrough infection (BTI) and reinfection convalescent plasma. Importantly, L455F single substitution significantly dampens receptor binding; however, the combination of L455F and F456L forms an adjacent residue flipping, which leads to enhanced NAbs resistance and ACE2 binding affinity. The perturbed receptor-binding mode leads to the exceptional ACE2 binding and NAb evasion, as revealed by structural analyses. Our results indicate the evolution flexibility contributed by epistasis cannot be underestimated, and the evolution potential of SARS-CoV-2 RBD remains high. The continuous evolution of SARS-CoV-2 presents a challenge to global public health and the development of vaccines and treatments against COVID-19. Recently, an adjacent residue alteration, L455F+F456L, also known as "FLip", on the receptor-binding domain of the virus, which has been identified in multiple strains of the virus, alters how the virus interacts with human cells and immune response. We show that the combination of these mutations synergistically increases the virus's ability to bind to ACE2, the primary receptor on cell surfaces, enabling it to specifically escape a public type of neutralizing antibodies elicited by vaccination and infection, and the molecular mechanisms are explained by structural analyses. The enhancement of receptor binding increases the potential of the virus to further accumulate immune evasive mutations. These findings broaden our understanding of SARS-CoV-2 evolution and highlight the importance of paying attention to these ongoing antigenic drifts in the virus as we continue to develop and evaluate current antibody therapeutics and vaccines.

Analysis of SARS-CoV-2 Variant Mutations Reveals Neutralization Escape Mechanisms and the Ability to Use ACE2 Receptors from Additional Species.

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage

Spike mutations in SARS-CoV-2 variants confer resistance to antibody neutralization

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization

Antibody evasion by the P.1 strain of SARS-CoV-2

Structural Basis for Continued Antibody Evasion by the SARS-CoV-2 Receptor Binding Domain

Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion

Characterization of SARS-CoV-2 Variants B.1.617.1 (kappa), B.1.617.2 (delta) and B.1.618 on Cell Entry, Host Range, and Sensitivity to Convalescent Plasma and ACE2 Decoy Receptor

Differential Escape of Neutralizing Antibodies by SARS-CoV-2 Omicron and Pre-Emergent Sarbecoviruses

Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity

Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding

Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant

Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera